In a cramped laboratory outside Tel Aviv, two brothers who cut their teeth in Israel's medical cannabis industry are wagering that naturally sourced psilocybin—not the synthetic kind gaining favor with Big Pharma—will find its place in the emerging psychedelic treatment landscape.
MSICS Pharma announced on May 3-4, 2026 that it had closed a $3.6 million seed round led by Fusion VC, with backing from an eclectic syndicate that includes GlenRock, the private investment arm of Leon Recanati, alongside Gooday Investments, Eyal Gura, Shani Investments, David Katzin, SGL Acquisitions, and a handful of other investors. The sum is modest by Silicon Valley standards, but sufficient, the company says, to expand production and push forward clinical trials across depression, OCD, and PTSD.
The company was founded by Roei and Omer Zerahia, both veterans of Canndoc, a medical cannabis producer that merged with InterCure, a publicly traded firm (NASDAQ: INCR) that posted revenues of 270.2 million shekels in fiscal year 2025. The brothers are positioning MSICS as something of a bridge between Israel's well-established cannabis expertise and the frontier science of psychedelic medicine.
A Rare License, a Bold Claim
What sets MSICS apart—at least according to coverage surrounding the funding announcement—is its regulatory foothold. The company claims to hold what several media outlets at the time characterized as the only Israeli and European license from the Ministry of Health for GMP (Good Manufacturing Practice) manufacturing of psilocybin for pharmaceutical use. That's a notable distinction in a field where regulatory clarity remains scarce and competitive moats are hard to establish.
The company's flagship candidate, MSX-06, is derived from mushrooms rather than synthesized in a lab. MSICS argues this preserves what it calls the "entourage effect," a term borrowed from cannabis research referring to the synergistic interactions of compounds found in the whole plant. Whether that claim holds up under rigorous clinical scrutiny remains an open question. Synthetic psilocybin has dominated late-stage trials to date, in part because it offers consistency and simpler regulatory pathways.
MSICS employed approximately a dozen people in Israel as of May 2026, a lean operation reflective of its early-stage status.
Trials Underway, Ambitions Outsize
The company is running Phase II studies in Israel targeting treatment-resistant depression and obsessive-compulsive disorder. There's also talk of a larger, multicenter trial for PTSD involving four Israeli hospitals and aiming to enroll 100 patients, though that effort was still awaiting regulatory approval as of the funding announcement. According to the company's website, MSX-06 is being tested across a spectrum of conditions—depression, OCD, anxiety, eating disorders—with patient recruitment actively underway at the time.
The seed capital, per company statements, will support three priorities: scaling up manufacturing capacity, accelerating the clinical pipeline, and preparing for commercial registration as new markets begin to crack open globally. MSICS has also received a nod from the Israel Innovation Authority, appearing in the agency's directory of grant recipients for a 2024 "Development to Manufacture" award in the biomedical sector.
Riding the Wave, or Getting Ahead of It?
The timing is perhaps more favorable than the founders might have expected just a few years ago. The psychedelic medicine sector, long confined to academic labs and the fringes of psychiatry, is inching toward mainstream acceptance. Compass Pathways, the London-based firm that has become the sector's most visible player, reported encouraging Phase 3 results for its synthetic psilocybin therapy in treatment-resistant depression earlier this year and is now gearing up for an FDA submission.
Closer to home, XTL Biopharmaceuticals announced in late April that it plans to acquire Psyga Bio, another Israeli company with a licensed, GMP-ready facility for both botanical and synthetic psilocybin production. The deal underscored a broader trend: Israel, already a hub for cannabis innovation, is positioning itself as a contender in psychedelics as well.
Still, the path from promising early-stage trials to approved medicine is long and littered with failures. Psilocybin therapy, even with favorable data, faces hurdles around dosing, administration, integration with psychotherapy, and reimbursement. And the question of whether naturally sourced formulations offer meaningful advantages over synthetic ones—beyond marketing appeal—remains unanswered.
For now, the Zerahia brothers are placing their bet. Whether MSICS becomes a footnote or a pioneer in the nascent psychedelic pharmaceutical industry will depend on data, regulatory fortune, and the whims of a market still finding its footing.
